Bio <-> Chem: Back-story on Novartis LCZ696 database links
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
Sacubitril | New Drug Approvals
Entresto | C96H120N12Na6O21 | CID 71449007 - PubChem
PharmaWiki - Sacubitril
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition | Circulation
Sacubitril - Wikipedia
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Sacubitril/Valsartan (LCZ696) | ARN Inhibitor | MedChemExpress
Neprilysin - Wikipedia
Frontiers | Neprilysin Inhibitors and Bradykinin
Sacubitril/valsartan - Wikipedia
File:Valsartan.svg - Wikipedia
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | NEJM
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition | Circulation
Sacubitril | New Drug Approvals
Sacubitril - Wikipedia
Entresto | C96H120N12Na6O21 | CID 71449007 - PubChem
Heart failure with preserved ejection fraction: emerging drug strategies. - Abstract - Europe PMC
